David Nierengarten
Stock Analyst at Wedbush
(3.82)
# 745
Out of 4,734 analysts
209
Total ratings
43.45%
Success rate
10.85%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Outperform | $135 → $124 | $110.05 | +12.68% | 3 | Jan 13, 2025 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $87 → $90 | $37.06 | +142.85% | 3 | Dec 2, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $40 → $47 | $43.13 | +8.97% | 7 | Nov 25, 2024 | |
| CMRX Chimerix | Reiterates: Outperform | $6 | $3.55 | +69.01% | 3 | Nov 18, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $14 | $9.50 | +47.37% | 8 | Nov 18, 2024 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $9.99 | +230.33% | 5 | Oct 25, 2024 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $20 | $3.43 | +483.09% | 2 | Oct 24, 2024 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $5 | $2.51 | +99.20% | 7 | Oct 22, 2024 | |
| INZY Inozyme Pharma | Reiterates: Outperform | $15 | $1.36 | +1,002.94% | 6 | Sep 30, 2024 | |
| ANAB AnaptysBio | Reiterates: Outperform | $42 | $15.85 | +164.98% | 12 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $75.84 | +51.64% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $6.16 | +273.38% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $9.58 | +108.77% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $12.25 | +226.53% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $20.62 | +118.23% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.40 | +316.67% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $6.53 | +175.65% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $58.25 | -2.14% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.95 | +427.43% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $519 → $560 | $640.52 | -12.57% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $18.54 | +83.39% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.61 | +91.57% | 8 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.50 | +33.33% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $8.03 | +24.53% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.01 | +298.01% | 6 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.33 | +727.07% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $19.24 | +87.11% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $5 | $1.27 | +293.70% | 14 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.89 | +315.22% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.44 | +143.17% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $34 | $8.35 | +302.40% | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.62 | +1,031.59% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $70 | $34.63 | +102.14% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $6.68 | +7,385.03% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $8.00 | +312.50% | 2 | Oct 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $4 | $0.66 | +505.97% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $53 → $46 | $26.17 | +75.77% | 7 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $5.54 | +242.96% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $40.00 | +87.50% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 | $0.22 | +40,920.97% | 3 | Jan 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.53 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $5.07 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.77 | - | 3 | Nov 20, 2017 |
Blueprint Medicines
Jan 13, 2025
Reiterates: Outperform
Price Target: $135 → $124
Current: $110.05
Upside: +12.68%
Apogee Therapeutics
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $37.06
Upside: +142.85%
Scholar Rock Holding
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $43.13
Upside: +8.97%
Chimerix
Nov 18, 2024
Reiterates: Outperform
Price Target: $6
Current: $3.55
Upside: +69.01%
Intellia Therapeutics
Nov 18, 2024
Reiterates: Neutral
Price Target: $14
Current: $9.50
Upside: +47.37%
Immunome
Oct 25, 2024
Reiterates: Outperform
Price Target: $33
Current: $9.99
Upside: +230.33%
Perspective Therapeutics
Oct 24, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.43
Upside: +483.09%
Nuvation Bio
Oct 22, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.51
Upside: +99.20%
Inozyme Pharma
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $1.36
Upside: +1,002.94%
AnaptysBio
Sep 26, 2024
Reiterates: Outperform
Price Target: $42
Current: $15.85
Upside: +164.98%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $75.84
Upside: +51.64%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $6.16
Upside: +273.38%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.58
Upside: +108.77%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $12.25
Upside: +226.53%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $20.62
Upside: +118.23%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.40
Upside: +316.67%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $6.53
Upside: +175.65%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $58.25
Upside: -2.14%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.95
Upside: +427.43%
Jul 26, 2024
Maintains: Outperform
Price Target: $519 → $560
Current: $640.52
Upside: -12.57%
Jul 23, 2024
Maintains: Outperform
Price Target: $30 → $34
Current: $18.54
Upside: +83.39%
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $2.61
Upside: +91.57%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.50
Upside: +33.33%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $8.03
Upside: +24.53%
May 14, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.01
Upside: +298.01%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.33
Upside: +727.07%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $19.24
Upside: +87.11%
May 10, 2024
Maintains: Neutral
Price Target: $7 → $5
Current: $1.27
Upside: +293.70%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.89
Upside: +315.22%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.44
Upside: +143.17%
Mar 19, 2024
Maintains: Neutral
Price Target: $60 → $34
Current: $8.35
Upside: +302.40%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.62
Upside: +1,031.59%
Feb 26, 2024
Maintains: Outperform
Price Target: $60 → $70
Current: $34.63
Upside: +102.14%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $6.68
Upside: +7,385.03%
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $8.00
Upside: +312.50%
Jul 26, 2023
Maintains: Neutral
Price Target: $7 → $4
Current: $0.66
Upside: +505.97%
Jun 7, 2023
Upgrades: Neutral
Price Target: $53 → $46
Current: $26.17
Upside: +75.77%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $5.54
Upside: +242.96%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $40.00
Upside: +87.50%
Jan 17, 2020
Downgrades: Neutral
Price Target: $90
Current: $0.22
Upside: +40,920.97%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $2.53
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $5.07
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $13.77
Upside: -